Source comparison
Sermorelin Help Low Testosterone Research: Peptide Comparison
The table below compares sermorelin to other peptides frequently studied in hypogonadism research contexts. Sermorelin (GRF 1-29) GHRH analog. Stimulates pulsatile GH release from pituitary somatotrophs Indirect, modest (8–15% above baseline), inconsistent acr
This comparison does not assign a generated winner or score.
- The table below compares sermorelin to other peptides frequently studied in hypogonadism research contexts.
- Sermorelin (GRF 1-29)
- GHRH analog. Stimulates pulsatile GH release from pituitary somatotrophs
- Indirect, modest (8–15% above baseline), inconsistent across studies
- Moderate increase (35–60% above baseline in responders)
- None. Preserves endogenous feedback loops
- Best for research models requiring intact HPTA and fertility preservation. Not a testosterone driver
- Ipamorelin
- Ghrelin mimetic. Stimulates GH release via ghrelin receptor (GHSR-1a)
- Indirect, minimal (similar to sermorelin but less studied)
- Moderate increase, slightly less than sermorelin
- None
- Preferred for studies requiring minimal cortisol or prolactin elevation. Similar testosterone profile to sermorelin
- CJC-1295 (DAC)
- Long-acting GHRH analog with drug affinity complex. Extends half-life to 6–8 days
- Indirect, variable (some studies show 10–20% increases with sustained use)
- Significant increase (60–90% above baseline with sustained elevation)
- Provides sustained GH elevation vs pulsatile. May offer slight advantage for metabolic permissiveness but still not a direct testosterone mechanism
- hCG (human chorionic gonadotropin)
- LH analog. Directly stimulates Leydig cells to produce testosterone
- Direct, significant (50–150% increases depending on baseline function)
- Minimal to none
- Moderate. Chronic high-dose use can desensitize LH receptors
- Gold standard for direct testosterone stimulation in research. Bypasses upstream GH/IGF-1 pathway entirely
- Enclomiphene
- Selective estrogen receptor modulator (SERM). Blocks hypothalamic estrogen receptors, increases endogenous LH/FSH
- Direct via LH increase, significant (30–80% above baseline in secondary hypogonadism)
- None. Restores rather than suppresses HPTA
- Most effective pharmacological option for secondary hypogonadism research without exogenous testosterone